Age: 35.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Echocardiogram, Electrocardiogram, Injection site swelling, Lymphadenopathy, Myalgia
Clinical narrative: Troponin, which is a cardiac enzyme or a heart test to be high; test continued to stay high for the 24 hours when they have done three different test at 8 hours apart; I might have myocarditis which is inflammation of the heart muscle as a result of the vaccine; I am having side effects affecting the heart because my cardiac enzymes are high; Rash that can happen from low platelet on both of my arm, for which I came to the emergency room; Rash that can happen from low platelet on both of my arm, for which I came to the emergency room; I am having side effects affecting skin because I am having rash; I am side effects affecting the immune system because my lymph nodes are enlarged; I have swelling at the site of injection; My lungs because I was wheezing; I was having lung symptoms; I have any irregular rhythm; I started having low grade fever and myalgia; I had similar low grade fever and myalgia with my first dose; I started having low grade fever and myalgia; I had similar low grade fever and myalgia with my first dose; I started having high grade fever, maximum temperature of 101.5 degree Fahrenheit; Wheezing; Dyspnea on excursion which is basically shortness of breath when I go up and down on the stairs; Chest tightness; This is a spontaneous report from a contactable Physician (patient).  A 35-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 14Jan2021 at single dose for covid-19 immunisation.  Medical history included asthma exercise induced from an unknown date and unknown if ongoing.  There were no concomitant medications.  The patient previously received the first dose of BNT162B2 on unknown date and experienced low grade fever and myalgia.  On 15Jan2021 the patient experienced Dyspnea on excursion which is basically shortness of breath when I go up and down on the stairs; Chest tightness; I started having high grade fever, maximum temperature of 101.5 degree Fahrenheit; Wheezing. On 16Jan2021 the patient experienced rash that can happen from low platelet on both of my arm, for which I came to the emergency room (hospitalization). On unknown date the patient experienced Troponin, which is a cardiac enzyme or a heart test to be high; test continued to stay high for the 24 hours when they have done three different test at 8 hours apart (hospitalization); I might have myocarditis which is inflammation of the heart muscle as a result of the vaccine (hospitalization); having side effects affecting the heart because my cardiac enzymes are high (hospitalization); I have any irregular rhythm; I started having low grade fever and myalgia; I had similar low grade fever and myalgia with my first dose; I am having side effects affecting skin because I am having rash; I am side effects affecting the immune system because my lymph nodes are enlarged; I have swelling at the site of injection; My lungs because I was wheezing; I was having lung symptoms. The patient underwent lab tests and procedures which included blood test: unknown results on unknown date; body temperature: 101.5 fahrenheit on 15Jan2021, chest x-ray: unknown results on unknown date; echocardiogram: unknown results on unknown date; EKG: unknown results on unknown date, cardiac enzyme: high on 16Jan2021, platelet count: low on  unknown date .  The outcome of the events was unknown.  Information on the lot/ batch number has been requested.; Sender's Comments: Based on the current available information and the plausible drug-event temporal association, a possible contributory role of the suspect product BNT162B2 to the development of reported serious events cannot be excluded.  The case will be reassessed if additional information becomes available.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.